The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called PF-07976016) for the potential treatment of obesity. The study will compare the experiences of participants taking the study medicine (PF-07976016) to those of participants who take placebo (a lookalike substance that contains no active study medicine). The aim is to measure the body's response to the study medicine, including any changes in participants' body weight and how well they tolerate the study medicine.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
263
Taken once daily
Taken once daily
Percent change from baseline in body weight
Time frame: Baseline to Week 16
Number of participants with treatment emergent adverse events
Time frame: From first dose (Day 1) up to 28-35 days after final dose, a total of approximately 21 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Anaheim Clinical Trials, LLC
Anaheim, California, United States
Artemis Institute for Clinical Research
San Diego, California, United States
Clinical & Translational Research Center
Aurora, Colorado, United States
University of Colorado Anschutz Medical Campus
Aurora, Colorado, United States
Westside Center for Clinical Research
Jacksonville, Florida, United States
New Horizon Research Center
Miami, Florida, United States
Renstar Medical Research
Ocala, Florida, United States
Renstar Medical Research
Ocala, Florida, United States
St Johns Center for Clinical Research
Saint Augustine, Florida, United States
Rophe Adult and Pediatric Medicine/SKYCRNG
Union City, Georgia, United States
...and 28 more locations